Pasadena, California 91105

  • Pain

Purpose:

The primary objective of this study is to evaluate the analgesic efficacy of hydrocodone bitartrate/acetaminophen immediate-release tablets at doses of 5.0 mg/325 mg, 7.5 mg/325 mg, and 10 mg/325 mg every 4 to 6 hours compared with placebo in treating patients with moderate to severe pain following bunionectomy


Criteria:

Inclusion Criteria: 1. Men and women aged 18 to 75 years, inclusive. 2. Patients who are scheduled to undergo a primary unilateral first metatarsal Austin bunionectomy with distal osteotomy and internal fixation without any collateral procedures (ie, uncomplicated procedure). 3. Patients who according to the American Society of Anesthesiologists Physical Status (PS) classification system are classified PS-1 (normal, healthy patient) or PS-2 (mild systemic disease). 4. The patient is able to speak English and is willing to provide written informed consent, including a written opioid agreement, to participate in the study. 5. The patient has a body mass index (BMI) between 18.0 and 33.0 kg/m2 (inclusive) at the time of screening. 6. The patient is in generally good health as determined by a medical history, medical examination, ECG, serum chemistry, hematology, urinalysis, and serology. 7. Women of childbearing potential (not surgically sterile or 2 years postmenopausal) must use a medically acceptable method of contraception and must agree to continue use of this method for the duration of the study and for 30 days after discontinuation of the study drug, unless they have exclusively same-sex partners. Acceptable methods of contraception include intrauterine device (IUD) known to have a failure rate of less than 1% per year, hormonal contraceptive (oral, implanted, transdermal, or injected), and barrier method with spermicide, abstinence, and partner vasectomy. NOTE: A woman will be considered surgically sterile if she has had a tubal ligation, hysterectomy, bilateral salpingo-oophorectomy or bilateral oophorectomy, or hysterectomy with bilateral salpingo-oophorectomy. 8. The patient, if a man, is surgically sterile, or, if capable of producing offspring, is currently using a medically acceptable method of contraception and agrees to continue use of this method for the duration of the study (and for 90 days after taking the last dose of the study drug because of the possible effects on spermatogenesis), unless he has exclusively same-sex partners. Acceptable methods of contraception include abstinence, barrier method with spermicide, female partner's use of steroidal hormonal contraceptive (oral, implanted, transdermal, or injected) in conjunction with a barrier method, female partner's use of an IUD known to have a failure rate of less than 1% per year, or if his female partner is surgically sterile or 2 years postmenopausal. In addition, male patients may not donate sperm for the duration of the study and for 90 days after taking study drug. 9. The patient must be willing and able to comply with study restrictions and to remain at the clinic for the required duration during the study, and willing to return to the clinic for the follow-up evaluation as specified in this protocol. 10. The patient must not participate in any other study involving an investigational agent while enrolled in the present study. 11. The patient must report a pain intensity score of ≥4 on an 11-point NPRS-11 within 9 hours after stopping postsurgical analgesia and immediately before randomization. 12. The patient should be free of any surgical or anesthetic complications after the surgery, which is to be performed using the intraoperative anesthetic regimen and the postoperative analgesic regimen that was followed appropriately without deviations that would confound analgesic assessments after receipt of the investigational product. Exclusion Criteria: 1. The patient has a chronic pain condition, excluding bunion pain that requires taking opioid analgesics within 30 days prior to surgery or use of non-opioid analgesics (acetylsalicylic acid, acetaminophen, nonsteroidal anti-inflammatory drugs) within 24 hours prior to surgery. Stable therapy of >30 days for acetylsalicylic acid (up to 81 mg/day) is allowed as cardiovascular prophylaxis. 2. Use of glucocorticoids (except nasal corticosteroid sprays and/or topical corticosteroids) for any condition within 6 months before study drug administration. 3. The patient uses any nonpharmacologic pain management techniques (eg, physical techniques, physiotherapy, massage therapy, acupuncture, biofeedback, and/or psychological support) and is unable or unwilling to discontinue prior to randomization (or study start). 4. The patient has any other medical or psychiatric condition or is receiving concomitant medication/therapy that would, in the opinion of the investigator, compromise the patient's safety, compliance with the study protocol procedures, or collection of data. 5. The patient has a clinically significant abnormality in the physical examination and/or clinical laboratory test values. 6. The patient is a pregnant or lactating woman. (Any woman becoming pregnant during the study will be withdrawn from the study.) 7. The patient has used an investigational drug within 1 month before the screening visit. 8. The patient is participating any currently ongoing research study. 9. The patient has any disorder that may interfere with gastrointestinal (GI) drug absorption (eg, gastric bypass surgery, lap band, malabsorption syndrome, and inflammatory bowel disease) or other condition that may have an effect on patient safety or efficacy aspects of participation in the opinion of the investigator. 10. The patient is allergic to or has had a serious reaction to hydrocodone or other opioids, acetaminophen, ropivacaine, lidocaine, ketorolac, ibuprofen, propofol, or any of the drugs required by the study protocol. 11. The patient has a recent history (within 5 years) or current evidence of alcohol or other substance abuse, with the exception of nicotine. 12. The patient has a positive urine drug screen (UDS) for cocaine, marijuana, opioids, amphetamines, methamphetamines, benzodiazepines, barbiturates, and/or methadone, unless explained by the use of prescription medication. 13. The patient has a history of suicidality as assessed by patient medical history and/or the C-SSRS. 14. The patient is expected to have elective surgery during the study other than a bunionectomy. 15. The patient has a history of malignancy within 5 years (except for treated basal cell carcinoma). 16. The patient has a positive test result for hepatitis B surface antigen or antibodies to hepatitis C, or known or tested positive for human immunodeficiency virus. 17. The patient has received a monoamine oxidase inhibitor (MAOI) within 14 days before the first dose of study drug. 18. The investigator believes that the patient is not suitable for the study for any reason.


Study is Available At:


Original ID:

TV46763-CNS-30031


NCT ID:

NCT02487108


Secondary ID:


Study Acronym:


Brief Title:

Study to Evaluate the Analgesic Efficacy and Safety of Hydrocodone Bitartrate/Acetaminophen Immediate-Release Tablets in Patients With Moderate to Sev


Official Title:

A Multicenter, Randomized, Double-blind, Placebo-controlled, Phase 3 Study to Evaluate the Analgesic Efficacy and Safety of Hydrocodone Bitartrate/Acetaminophen Immediate-Release Tablets (TV-46763) at Doses of 5.0 mg/325 mg, 7.5 mg/325 mg, and 10 mg/325 m


Overall Status:

Completed


Study Phase:

Phase 3


Genders:

N/A


Minimum Age:

18 Years


Maximum Age:

75 Years


Quick Facts

Healthy Volunteers
Oversight Has DMC
Study Is FDA Regulated
Study Is Section 801
Has Expanded Access

Study Source:

Teva Pharmaceutical Industries


Oversight Authority:

United States: Food and Drug Administration


Reasons Why Stopped:


Study Type:

Interventional


Study Design:


Number of Arms:

4


Number of Groups:

0


Total Enrollment:

569


Enrollment Type:

Actual


Overall Contact Information

Official Name:Teva Medical Expert, MD
Study Director
Teva Pharmaceuticals USA

Study Dates

Start Date:August 11, 2015
Completion Date:March 30, 2016
Completion Type:Actual
Primary Completion Date:March 30, 2016
Primary Completion Type:Actual
Verification Date:June 2018
Last Changed Date:June 27, 2018
First Received Date:June 29, 2015

Study Outcomes

Outcome Type:Primary Outcome
Measure:Summed pain intensity difference (SPID48) Numerical pain rating
Time Frame:48 Hours
Safety Issues:False
Description:11-point numerical pain rating scale (NPRS-11), where 0=no pain and 10=the most intense pain imaginable
Outcome Type:Secondary Outcome
Measure:Summed pain intensity difference (SPID) scores
Time Frame:0-6, 0-12, 0-24, and 0-36 hours
Safety Issues:False
Description:Time-interval weighted SPID scores 0=no pain and 10=the most intense pain imaginable
Outcome Type:Secondary Outcome
Measure:Pain intensity difference (PID)
Time Frame:0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 5, and 6 hours
Safety Issues:False
Outcome Type:Secondary Outcome
Measure:Time to peak PID
Time Frame:Within 6 hours
Safety Issues:False
Outcome Type:Secondary Outcome
Measure:Proportion of patients with a 30% - 50% reduction in pain intensity
Time Frame:6, 12, 24, and 48 hours
Safety Issues:False
Outcome Type:Secondary Outcome
Measure:Time to onset of perceptible and meaningful pain relief
Time Frame:0.25, 0.5, 0.75, 1 hours after first dose
Safety Issues:False
Outcome Type:Secondary Outcome
Measure:Total rescue medication use
Time Frame:6, 12, 24, and 48 hours
Safety Issues:False
Outcome Type:Secondary Outcome
Measure:Proportion of patients taking rescue medication
Time Frame:6, 12, 24, and 48 hours
Safety Issues:False
Outcome Type:Secondary Outcome
Measure:Percentage of participants with adverse events
Time Frame:48 hours
Safety Issues:False

Study Interventions

Intervention Type:Drug
Name:Hydrocodone bitartrate
Description:5.0 mg, 7.5 mg, 10 mg
Arm Name:Hydrocodone bitartrate/acetaminophen 5.0 mg/325 mg
Intervention Type:Drug
Name:Acetaminophen
Description:325 mg
Arm Name:Hydrocodone bitartrate/acetaminophen 5.0 mg/325 mg
Intervention Type:Drug
Name:Placebo
Description:Matching Placebo
Arm Name:Matching placebo

Study Arms

Study Arm Type:Experimental
Arm Name:Hydrocodone bitartrate/acetaminophen 5.0 mg/325 mg
Description:every 4 to 6 hours
Study Arm Type:Experimental
Arm Name:Hydrocodone bitartrate/acetaminophen 7.5 mg/325 mg
Description:every 4 to 6 hours
Study Arm Type:Experimental
Arm Name:Hydrocodone bitartrate/acetaminophen 10 mg/325 mg
Description:every 4 to 6 hours
Study Arm Type:Placebo Comparator
Arm Name:Matching placebo
Description:every 4 to 6 hours

Study Agencies

Agency Class:Industry
Agency Type:Lead Sponsor
Agency Name:Teva Branded Pharmaceutical Products, R&D Inc.
Agency Class:Other
Agency Type:Collaborator
Agency Name:INC Research

Sample and Retention Information

There are no available Sample and Retention Information

Study References

There are no available Study References

Data Source: ClinicalTrials.gov

Date Processed: April 03, 2020

Modifications to this listing: Only selected fields are shown, please use the link below to view all information about this clinical trial.


This study is not currently recruiting Study Participants. The form below is not enabled.